Pacira BioSciences, Inc. PCRX Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $726.41M+3.6% | $700.97M+3.9% | $674.98M+1.2% | $666.82M+23.1% | ||
| $149.75M-12.1% | $170.43M-7.7% | $184.67M-7.3% | $199.3M+42.1% | ||
| $576.66M+8.7% | $530.54M+8.2% | $490.31M+4.9% | $467.53M+16.5% | ||
| 79.4%+3.7pp | 75.7%+3.0pp | 72.6%+2.5pp | 70.1%-4.0pp | ||
| $116.96M+43.4% | $81.58M+7.0% | $76.26M-10.1% | $84.8M+52.7% | ||
| $368.76M+25.4% | $294.1M+9.2% | $269.44M+5.9% | $254.52M+27.7% | ||
| $707.22M-8.7% | $774.34M+31.8% | $587.3M-3.2% | $606.8M+34.4% | ||
| $19.19M— | —— | $87.68M— | —— | ||
| 2.6%— | —— | 13%— | —— | ||
| $17.45M+5.3% | $16.57M-18.4% | $20.31M-49.2% | $39.98M+25.9% | ||
| -$2.32M-123% | $10.27M+139% | -$26.53M+43.2% | -$46.72M-39.4% | ||
| $16.87M— | —— | $61.7M— | —— | ||
| —— | $36.45M+84.6% | $19.75M+857% | -$2.61M-117% | ||
| $7.03M— | —— | $41.96M— | —— | ||
| 1%— | —— | 6.2%— | —— | ||
| $0.15— | —— | $0.83— | —— | ||
| $110.21M— | —— | $163.25M— | —— | ||
| 15.2%— | —— | 24.2%— | —— | ||
| $19.19M— | —— | $87.68M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Pacira BioSciences, Inc.'s revenue?
- Pacira BioSciences, Inc. (PCRX) generated $734.9M in revenue over the trailing twelve months, up 4.6% year over year.
- Is Pacira BioSciences, Inc. profitable?
- Pacira BioSciences, Inc. reported $5.1M in net income over the trailing twelve months, a 0.7% net margin.
- What are Pacira BioSciences, Inc.'s profit margins?
- Gross margin is 79.3% and operating margin is 3.3%, with a 0.7% net margin.
- What is Pacira BioSciences, Inc.'s earnings per share?
- Pacira BioSciences, Inc.'s diluted EPS over the trailing twelve months is $0.12.
- Where does Pacira BioSciences, Inc.'s income statement data come from?
- Every line is extracted from Pacira BioSciences, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
